Aurobindo Pharma has received approval from the US Food and Drug Administration (FDA) to market its 300 mg Cefdinir Capsules.

Aurobindo Pharma has received US FDA approval to market its Abbreviated New Drug Application (ANDA) Cefdinir Capsules in the US market. Cefdinir is used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. This is the 62nd ANDA approval received by the company.

The drug is a generic equivalent of Abbott Laboratories Omnicef capsules. Omnicef capsules are used to treat patients, with mild to moderate infections caused by susceptible strains of micro-organisms.